Check the spelling or try searching for a more general term.
The glaucoma medications used to control the IOP of refractive patients often add to the blurred vision experienced by these patients on a daily basis. This leaves the refractive surgeon with the frustrating task of correcting refractive error without being able to eliminate a key contributor to the problem.
Quantel Medical has completed its acquisition of Ellex, including the company’s laser and ultrasound technology solutions (with the exception of 2RT® and iTrack®), via the financial holding company Lumibird Medical.
The coming together of these two companies—both renowned in the field of ophthalmology—represents a real milestone in their history. Quantel Medical and Ellex have a shared heritage in the development of cutting-edge technologies for the diagnosis and treatment of the leading causes of blindness worldwide: glaucoma, cataracts, AMD and diabetic retinopathy.
